Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial"
- PMID: 35152142
- PMCID: PMC9064955
- DOI: 10.1016/j.jcrc.2022.153995
Letter to the Editor: "Midodrine to liberate ICU patients from intravenous vasopressors: Another negative fixed-dose trial"
Conflict of interest statement
Declaration of Competing Interest None.
Comment in
-
Randomised-control trials do not support midodrine as an intravenous vasopressor weaning strategy.J Crit Care. 2022 Dec;72:153996. doi: 10.1016/j.jcrc.2022.153996. Epub 2022 Jan 31. J Crit Care. 2022. PMID: 35115215 No abstract available.
Comment on
-
A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study.J Crit Care. 2022 Feb;67:166-171. doi: 10.1016/j.jcrc.2021.11.004. Epub 2021 Nov 18. J Crit Care. 2022. PMID: 34801917 Clinical Trial.
References
-
- Costa-Pinto R, Yong ZT, Yanase F, et al. A pilot, feasibility, randomised controlled trial of midodrine as adjunctive vasopressor for low-dose vasopressor-dependent hypotension in intensive care patients: The MAVERIC study. J Crit Care. 2022;67:166–71. DOI: 10.1016/j.jcrc.2021.11.004. - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
